Dr. Qi Liang is the Senior Director of Antibody Discovery in Kymab Limited, a Cambridge-based leading biopharmaceutical company. With private financing from Wellcome Trust, Bill & Melinda Gates Foundation, Kymab has been supported to establish a mature and long-term vision for success in tackling some of the most challenging diseases. Dr Liang is a founding scientist of Kymab. She is one of the major contributors to invent and establish Kymab’s IntelliSelect® Transgenic platforms capable of rapidly generating an exceptionally broad diversity and high quality of fully human antibodies against challenging disease targets. Her team also developed the IntelliSelect® Screening technology combining single-cell sequencing, genomics and proprietary bioinformatic algorithms to prioritize and select antibodies generated by our IntelliSelect® Transgenic platforms that have the most desirable drug-like properties. Dr Liang is the author of over 10 scientific articles, and the inventor of 40 granted patents and over 92 patent applications.